S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
CGC   21.88 (-1.93%)
NVDA   294.07 (-4.74%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
Log in

NASDAQ:MRNS - Marinus Pharmaceuticals Stock Price, Forecast & News

$2.84
-0.20 (-6.58 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$2.71
Now: $2.84
$2.89
50-Day Range
$2.01
MA: $2.18
$2.70
52-Week Range
$0.77
Now: $2.84
$5.40
Volume41,991 shs
Average Volume853,845 shs
Market Capitalization$152.99 million
P/E RatioN/A
Dividend YieldN/A
Beta3.22
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRNS
CUSIPN/A
Phone484-801-4670

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.30 per share

Profitability

Net Income$-36,730,000.00

Miscellaneous

Employees28
Market Cap$152.99 million
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive MRNS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.


Marinus Pharmaceuticals (NASDAQ:MRNS) Frequently Asked Questions

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) announced its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.02. View Marinus Pharmaceuticals' Earnings History.

When is Marinus Pharmaceuticals' next earnings date?

Marinus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Marinus Pharmaceuticals.

What price target have analysts set for MRNS?

6 brokers have issued 12 month target prices for Marinus Pharmaceuticals' shares. Their forecasts range from $1.70 to $10.00. On average, they expect Marinus Pharmaceuticals' stock price to reach $5.95 in the next year. This suggests a possible upside of 109.5% from the stock's current price. View Analyst Price Targets for Marinus Pharmaceuticals.

What is the consensus analysts' recommendation for Marinus Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Marinus Pharmaceuticals.

What are Wall Street analysts saying about Marinus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Marinus Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut. " (11/12/2019)
  • 2. LADENBURG THALM/SH SH analysts commented, "We find this is the right and not completely unexpected decision considering his enthusiasm in developing ganaxolone, his broad experience in companies and as an investor, as well as the need for strong stewardship at this time." (8/9/2019)
  • 3. Cantor Fitzgerald analysts commented, "Given the compelling Phase 2 data announced in CDD, market size potential in PPD (with positive interim data reported in 4Q18), and undervaluation relative to peers, we believe Marinus shares offer a compelling risk-reward profile. Valuation Summary We arrive at our 12-month PT of $22/share by assessing the after-tax, risk-adjusted NPV of potential future cash flows from ganaxolone for the treatment of postpartum depression and CDKL5 deficiency disorder." (5/1/2019)

Has Marinus Pharmaceuticals been receiving favorable news coverage?

News coverage about MRNS stock has trended somewhat positive this week, InfoTrie reports. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Marinus Pharmaceuticals earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the company's share price in the near future. View News Stories for Marinus Pharmaceuticals.

Are investors shorting Marinus Pharmaceuticals?

Marinus Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 4,580,000 shares, an increase of 56.3% from the January 15th total of 2,930,000 shares. Based on an average trading volume of 1,560,000 shares, the days-to-cover ratio is currently 2.9 days. Currently, 9.9% of the company's stock are short sold. View Marinus Pharmaceuticals' Current Options Chain.

Who are some of Marinus Pharmaceuticals' key competitors?

What other stocks do shareholders of Marinus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marinus Pharmaceuticals investors own include Nordic American Tanker (NAT), The Gabelli Dividend & Income Trust (GDV), Micron Technology (MU), Realty Income (O), Advanced Micro Devices (AMD), Amarin (AMRN), Novavax (NVAX), TG Therapeutics (TGTX), XOMA (XOMA) and Exelixis (EXEL).

Who are Marinus Pharmaceuticals' key executives?

Marinus Pharmaceuticals' management team includes the folowing people:
  • Mr. Edward F. Smith, VP, CFO, Treasurer & Sec. (Age 48)
  • Mr. Christopher Michael Cashman, CEO, Pres & Director (Age 62)
  • Dr. Lorianne K. Masuoka, Chief Medical Officer (Age 58)
  • Dr. Scott Braunstein, Exec. Chairman (Age 56)
  • Ms. Lisa M. Caperelli, Exec. Director of Investor & Strategic Relations

Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (11.03%), Boxer Capital LLC (8.91%), Granite Point Capital Management L.P. (5.01%), Alyeska Investment Group L.P. (4.09%), State Street Corp (1.70%) and Geode Capital Management LLC (1.30%). Company insiders that own Marinus Pharmaceuticals stock include Christopher Michael Cashman, Edward F Smith and Scott Braunstein. View Institutional Ownership Trends for Marinus Pharmaceuticals.

Which institutional investors are selling Marinus Pharmaceuticals stock?

MRNS stock was sold by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P., State Street Corp, Bank of America Corp DE and Barclays PLC. View Insider Buying and Selling for Marinus Pharmaceuticals.

Which institutional investors are buying Marinus Pharmaceuticals stock?

MRNS stock was purchased by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Alyeska Investment Group L.P., Bain Capital Life Sciences Investors LLC, Asymmetry Capital Management L.P., Oxford Asset Management LLP, Jacobs Levy Equity Management Inc., Geode Capital Management LLC and Alambic Investment Management L.P.. View Insider Buying and Selling for Marinus Pharmaceuticals.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $2.84.

How big of a company is Marinus Pharmaceuticals?

Marinus Pharmaceuticals has a market capitalization of $152.99 million. The biopharmaceutical company earns $-36,730,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Marinus Pharmaceuticals employs 28 workers across the globe.View Additional Information About Marinus Pharmaceuticals.

What is Marinus Pharmaceuticals' official website?

The official website for Marinus Pharmaceuticals is http://www.marinuspharma.com/.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 100, Radnor PA, 19087. The biopharmaceutical company can be reached via phone at 484-801-4670 or via email at [email protected]


MarketBeat Community Rating for Marinus Pharmaceuticals (NASDAQ MRNS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  349 (Vote Outperform)
Underperform Votes:  286 (Vote Underperform)
Total Votes:  635
MarketBeat's community ratings are surveys of what our community members think about Marinus Pharmaceuticals and other stocks. Vote "Outperform" if you believe MRNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel